Pregabalin Capsule
Product Images NDC 71205-639

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-639). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

71205-639-30 (Pregabalin 100mg 90s)

71205-639-30 (Pregabalin 100mg 90s)
This is a description of a medication. The medication is called Pregabalin 100mg and is packaged by Proficient Rx LP in Thousand Oaks, California under NDC 71205-639-30. The medication is in capsule form, with each hard gelatin capsule containing 100mg of pregabalin. The capsules are orange in color and are imprinted with "A010" on the cap and "PREG 100" on the body. The lot number is 000 and the expiration date is not provided. The medication is only available with a prescription and comes in a package of 30 capsules. The accompanying medication guide should be provided to each patient, and the medication should be kept out of the reach of children.*
FDA Label Image

Pregabalin-equation (Pregabalin Equation)

Pregabalin-equation (Pregabalin Equation)
This text appears to be a medical formula that may be used for calculating certain medical values. The formula involves age, weight, and serum creatinine to determine CLCr for female patients. However, the characters are not clear and some of them are unreadable, making it difficult to provide an accurate description.*
FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

Pregabalin-figure-6 (Pregabalin Figure 6)
This appears to be a table of results from two different studies (E1 and E3) comparing the effectiveness of various doses of a drug versus a placebo. The table shows the percentage of participants who experienced a positive outcome (not specified) for each treatment group in each study. The highest dose group (600 mg/day) appears to have shown a statistically significant improvement compared to the placebo group.*
FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

Pregabalin-figure-7 (Pregabalin Figure 7)
FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

Study Dpn 1 (Pregabalin Image 1)
FDA Label Image

Study Sci 1 (Pregabalin Image 10)

Study Sci 1 (Pregabalin Image 10)
FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

Pain Intensity-study Sci 2 (Pregabalin Image 11)
FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

Study Dpn 2 (Pregabalin Image 2)
FDA Label Image

Study Phn 1 (Pregabalin Image 3)

Study Phn 1 (Pregabalin Image 3)
FDA Label Image

Study Phn 2 (Pregabalin Image 4)

Study Phn 2 (Pregabalin Image 4)
Percentage Improvement in Pain from Baseline for Patients Improved using Pregabalin 200mg three times a day and Pregabalin 100mg three times a day compared to Placebo. The string of characters "o238 888 8I 88" cannot be identified or interpreted, hence not-available.*
FDA Label Image

Study Phn 3 (Pregabalin Image 5)

Study Phn 3 (Pregabalin Image 5)
FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

Fibromyalgia Study F1 (Pregabalin Image 8)
This is a report showing the percent improvement of patients who were administered pregabalin at different daily doses. It also shows the percent improvement in pain from baseline for each of the doses.*
FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

Fibromyalgia Study F2 (Pregabalin Image 9)
FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Pregabalin Structure (Pregabalin Srtuc 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.